Home›Trial›NCT07349537
🔬NCT07349537Phase 1RECRUITING

Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors

Study Summary

The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of RMC-5127 as a monotherapy and in combination with either daraxonrasib or cetuximab in adults with KRAS G12V-mutant solid tumors.

Conditions
Non-small Cell Lung Cancer (NSCLC)Colorectal Cancer (CRC)Pancreatic AdenocarcinomaPancreatic Ductal Adenocarcinoma (PDAC)PDACCRCNSCLCPancreatic CancerLung Cancer (NSCLC)Advanced Solid Tumors
Interventions / Drugs
RMC-5127daraxonrasibcetuximab
View on ClinicalTrials.gov ↗
Sponsor
RVMD
Revolution Medicines
Precision Oncology
F35/100
Study Details
Enrollment574 participants
Primary Completion—
Lead SponsorRevolution Medicines, Inc.
Data Retrieved2026-04-11 04:26:28.070717+00:00
Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.